Video

Dr. Weber discusses cardiovascular safety of vibegron in patients with OAB

Author(s):

Urology Times staff

“The take-home message is vibegron is a very safe drug and there are no concerns about any kind of cardiovascular adverse effects,” says Michael A. Weber, MD.

In this video, Michael A. Weber, MD, discusses the takeaways of the study, “Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind study,” presented at the 2021 American Urological Association Annual Meeting. Weber is a professor of medicine and associate dean of research at Downstate College of Medicine, State University of New York, Brooklyn, New York.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
DNA helix | Image Credit: © BillionPhotos.com - stock.adobe.com
Woman typing on laptop | Image Credit: © Gorodenkoff - stock.adobe.com
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Related Content
iTNM may provide comparable safety, efficacy to SNM for OAB, UUI
November 4th 2024

iTNM may provide comparable safety, efficacy to SNM for OAB, UUI

Hannah Clarke
The UUI responder rate was 71.8% among those who received SNM and 71.3% among those who received iTNM.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Comparable efficacy seen with single vs. multiple OnabotulinumtoxinA injection sites in OAB
October 24th 2024

Comparable efficacy seen with single vs. multiple OnabotulinumtoxinA injection sites in OAB

Hannah Clarke
At 1 month, the mean decrease in the OAB-Q symptom severity subscale score was -31.2 in the 1-injection cohort vs -39.5 in the 10-injection cohort.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
New telehealth service provides access to Leva System for urinary incontinence
August 13th 2024

New telehealth service provides access to Leva System for urinary incontinence

Hannah Clarke
Data from a real-world evidence study of the Leva System were recently published in JMIR Formative Research, supporting the safety and effectiveness of the program in the treatment of patients with urinary incontinence.
Trial progresses of SNM device for urge urinary incontinence
July 23rd 2024

Trial progresses of SNM device for urge urinary incontinence

Hannah Clarke
Data from phase 2 of the SANS-UUI trial are expected to support an application to the FDA for approval of the device in patients with urge urinary incontinence.
© 2024 MJH Life Sciences

All rights reserved.